In 2017, there were over 550,000 estimated new cases of multi-drug/rifampicin resistant 37 tuberculosis (MDR/RR-TB), emphasizing a need for new treatment strategies. Linezolid (LZD) 38 is a potent antibiotic for antibiotic-resistant Gram-positive infections and is an effective treatment 39 for TB. However, extended LZD use can lead to LZD-associated host toxicities, most commonly 40 bone marrow suppression. LZD toxicities may be mediated by IL-1, a pathway important for 41 early immunity during M. tuberculosis infection that later contributes to pathology. We 42 hypothesized LZD efficacy could be enhanced by modulation of IL-1 pathway to reduce BM 43 toxicity and TB associated-inflammation. We used two animal models of TB to test our 44 hypothesis, mice and cynomolgus macaques. Antagonizing IL-1 in chronically-infected mice 45 reduced lung neutrophil numbers and partially restored the erythroid progenitor populations that 46 are depleted by LZD. In macaques, we found no conclusive evidence of BM suppression 47 associated with LZD, indicating our treatment time may have been short enough to avoid the 48 toxicities observed in humans. Though treatment was only 1 month, the majority of granulomas 49 were sterilized with reduced inflammation (assessed by PET/CT) in animals treated with both 50 LZD and IL-1 receptor antagonist (IL-1Rn). However, overall lung inflammation was significantly 51 reduced in macaques treated with both IL-1Rn and LZD, compared to LZD alone. Importantly, 52 IL-1Rn administration did not noticeably impair the host response against Mtb or LZD efficacy in 53 either animal model. Together, our data support that inhibition of IL-1 in combination with LZD 54 has potential to be an effective HDT for TB.
The IL-1R1 blocking antibody aIL-1R1 was next tested in combination with LZD to determine 161 whether the efficacy or toxicity of the antibiotic was altered. C3HeB/FeJ mice, which are 162 relatively susceptible to Mtb and develop histopathological lesions that more closely resemble 163 human disease, were used for these studies. Mice with established disease were treated 164 between days 28 and 46 post-infection with vehicle alone, LZD, aIL-1R1 or a combination of the 165 two. As previously reported, LZD was effective in this model, reducing lung neutrophil numbers, 166 bacterial burden and weight loss ( Fig. 2 A-D) (23). The addition of aIL-1R1 to this regimen 167 further reduced lung neutrophil numbers, and did not significantly alter the antimicrobial activity 168 of LZD. As IL-1b production in response to both Mtb infection and LZD treatment depends 169 largely on the NLRP3 inflammasome, we also investigated a regimen in which LZD and a small 170 molecule NLRP3 inhibitor (MCC950) was administered between days 56 and 77 post-infection.
171
As observed with aIL-1R1, the addition of MCC950 reduced PMN numbers in the lung, relative 172 to LZD alone, and did not significantly alter the rate of bacterial killing (Fig. 2 E-G) . Using a 173 more rapid treatment protocol and C57BL/6 mice with genetic deficiencies in Caspase 1 or 174 NLRP3, we confirmed that the antimicrobial activity of LZD was unaffected by inflammasome 175 activation ( Supplementary Fig. 1 ). Mice were treated between days 14 and 28 post-infection 176 and the effect of LZD on bacterial burden and lung neutrophil number was at least as large in 177 the knockout animals as the wild type controls.
179
Hematopoietic suppression was assayed in bone marrow and spleens of C3HeB/FeJ mice.
180
Both organs are significant sites for hematopoiesis in small animals, in which the bone marrow 181 has insufficient capacity, particularly when the requirement for blood cells increases. Using flow 182 cytometry, erythroid progenitors can be divided into a progression of precursors; pro-erythrocyte 183 (ProE), EryA, EryB, and EryC (Fig. 3A) . These populations were quantified in each tissue of 8 had a profound effect, nearly eliminating early erythroid progenitors of the ProE, EryA and EryB 186 classes ( Fig. 3B-E ). Simultaneous treatment with aIL-1R1 largely reversed the effect of LZD in 187 the spleen, restoring these immature precursors to approximately half of their untreated levels.
188
While aIL-1R1 also significantly increased the number of erythroid precursors in the BM, the 189 suppression of LZD toxicity was less pronounced at this site.
191
In sum, studies in the mouse model indicated that the addition of aIL-1R1 to an LZD regimen 192 could reduce the number of lungs PMN and ameliorate hematopoietic toxicity, while not 193 compromising antimicrobial activity. These observations justified further studies in a non-human 194 primate model.
196

Changes in TB disease in macaques treated with LZD and HDT by PET/CT 197
Previously we published the efficacy and pharmacokinetics of LZD in cynomolgus macaques 198 treated for 8 weeks with a single daily dose of 30 mg/kg (14). To adhere to FDA guidelines for 199 LZD administration at the time we initiated this study, and reproduce clinical exposure at 600 mg 200 twice daily (b.i.d.), we shortened treatment duration to 4 weeks and increased the dosing 201 frequency to 30 mg/kg b.i.d. Dose finding studies were carried out in uninfected cynomolgus 202 macaques to ensure that adequate drug concentrations similar to those achieved in patients at 203 600 mg b.i.d. were reached in the blood (Supplementary Fig. 2A ).
205
To assess this HDT/LZD regimen, we infected 10 cynomolgus macaques with Mtb strain 206 Erdman (12 CFU via bronchoscope) and monitored development of active TB disease (~3-5 207 months) ( Supplementary Table 1 and Supplementary Fig. 2B ). The macaques were then 208 randomized to a 4-week drug regimen of LZD (n=5) or LZD+IL-1Rn (n=5) ( Supplementary Fig. 
209
2B). One advantage of this model is the ability to track disease progression throughout infection 9 and treatment using serial 18 F-FDG PET CT scans (14, 24). Lung inflammation was quantified 211 by total FDG activity in the lungs before and during treatment ( Fig. 4A (19) . In LZD treated macaques, there was no significant decrease in total lung FDG 213 activity after 4 weeks (p=0.2876), although there was a trend for an initial reduction in 214 inflammation after 2 weeks of treatment (p=0.0857)( Fig. 4B ). In contrast, LZD+IL-1Rn treatment 215 resulted in a significant reduction in total lung FDG activity after 2 and 4 weeks (p=0.0242, 216 p=0.0237 respectively). We assessed changes in granulomas during treatment by measuring as extrapulmonary lesions, as previously described (20) . Total thoracic CFU (lung + lymph 237 nodes) was not significantly different between LZD and LZD + IL-1Rn macaques (p = 0.1508) 238 ( Fig. 5A) , with similar frequencies of sterilized granulomas (LZD = 68.42%, LZD+IL-1Rn = 239 72.22%). In the current study, we did not have untreated control macaques, so we provide total 240 thoracic CFU for 3 similarly infected historical controls (untreated) for reference; these data 241 were excluded from statistical analyses. This supports that high dose LZD as a single drug is 242 effective at killing bacteria even in a short (4 week) regimen. Bacterial burden in CFU+ thoracic 243 lymph nodes was similar between the groups though trended towards lower CFU in LZD+IL-244 1Rn treated macaques (p=0.0965) ( Fig 5B) . We previously reported that a 2-month lower dose 245 regimen of LZD could reduce bacterial burden compared to untreated controls, with ~80% 246 sterilized granulomas (14). Since the bacterial burden in macaques with active TB can vary 247 substantially, we estimated the pre-treatment total thoracic CFU from the total lung FDG by PET 248 CT as previously described (20) , and compared the actual bacterial burden post-treatment 249 against the estimated pre-treatment value. All macaques, regardless of treatment group, had 250 lower total thoracic CFU at necropsy compared to the estimated total thoracic CFU prior to 251 treatment initiation ( Fig. 5C ). Our data indicate that while IL-1Rn did not significantly enhance 252 bacterial killing, it did not impair LZD-mediated bacterial clearance.
254
Lack of LZD-induced bone marrow suppression in macaques 255
In humans, LZD is associated with host toxicities during extended treatment periods of > 4 256 weeks (25). To determine whether bone marrow suppression occurred during the 4-week high 257 dose LZD therapy and whether IL-1Rn could modulate observable host toxicities, we isolated 258 bone marrow at necropsy from the sternum of each macaque and assessed erythropoietic 259 progenitor populations and mitochondrial function by flow cytometry (Fig. 6A ). During 
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(pooled groups) (p=0.0098). This observation was similar to that observed in mice (Fig 2A) . To 
IL-1 blockade modulates granuloma specific responses and healing dynamics 302
To determine whether IL-1Rn modulated immune responses at the site of infection, we chose at 303 random 5 granulomas per animal (25 per treatment group) and performed a multi-plex analysis 304 of granuloma supernatants (Fig. 8A ). There were no significant differences in IL-1b, IL-1RA, or 13 IL-18 levels, which are associated with the IL-1 pathway. IL-2 and IL-17 are correlated with 306 protective immune responses during TB (26); there was a trend for higher IL-2 levels in LZD+IL-307 1Rn treatment and a statistically significant increase in IL-17a in LZD+IL-1Rn treated animals.
308
G-CSF/CSF-3 levels were significantly higher in LZD+IL-1Rn treated granulomas, providing Fibrosis is modulated by the IL-1 pathway, however while fibrosis is associated with 371 granuloma healing, lung fibrosis can cause secondary complications after TB disease 372 resolution (2) . We have shown in previous studies that drug therapy for TB induces 373 fibrotic healing in granulomas (31, 32). Therefore, we assessed whether IL-1Rn was 374 associated with changes in granuloma pathology. While we did not observe a 375 significant difference in the frequency of fibrotic versus non-fibrotic granulomas 376 (p=0.1531), there was a significant decrease in necrotizing granulomas when IL-1Rn 377 was added to LZD therapy. Thus, although there is no synergistic effect between IL-378 1Rn and LZD in promoting fibrosis associated with drug clearance, the reduction in 379 neutrophils could skew granuloma resolution towards a non-necrotizing, fibrotic lesion. 380
381
We also assessed LZD-associated bone marrow suppression and reversal with IL-1Rn 382 therapy. We designed our HDT to match the current FDA guidelines for LZD and IL-383 1Rn schedules, which resulted in a lack of observable bone marrow suppression in 384 macaques. In mice however, LZD-induced bone marrow suppression was reduced with 385 the addition of IL-1R1 antagonists, supporting our initial hypothesis. The role of IL-1 386 signaling is consistent with the ability of IL-1 to suppress erythropoiesis in mice by 387 reducing the number of progenitors (33). The remaining deficit in erythropoiesis during 388 IL-1 blockade could reflect either incomplete inhibition by IL-1Rn or an independent role 389 of inflammasome activation. Optimizing this effect will require further work to 390 understand the relative roles of IL-1 signaling and inflammasome activation. 391
392
Our data support and extend our previous data in macaques that LZD has excellent 393 efficacy against TB, even as a single-drug given for only 4-weeks, providing additional 394 support for LZD as an antimicrobial for MDR/XDR-TB cases (12). IL-1Rn therapy in 395 conjunction with LZD was successful in reducing TB-associated inflammation with no 396 negative effects on Mtb clearance, however additional studies addressing long-term 397 effects on immune responses and TB disease resolution are needed. Anakinra (IL-1Rn) 398
is already FDA-approved for adult and pediatric use in other inflammatory disorders; our 399 data provide pre-clinical evidence that IL-1Rn could be a potential therapy for cases of 400 severe TB to quell excessive inflammation and improve standard therapies. Our study 401 highlights the potential of HDTs for TB but also the necessity of assessment in 402 translational models prior to implementation in human trials. 
Policy. 414
All macaques used in this study were housed at the University of Pittsburgh in rooms 415 with autonomously controlled temperature, humidity, and lighting. Animals were singly 416 housed in caging at least 2 square meters that allowed visual and tactile contact with 417 neighboring conspecifics. The macaques were fed twice daily with biscuits formulated 418 for nonhuman primates, supplemented at least 4 days/week with large pieces of fresh 419 fruits or vegetables. Animals had access to water ad libitem. Because our macaques 420 were singly housed due to the infectious nature of these studies, an enhanced 421 enrichment plan was designed and overseen by our nonhuman primate enrichment 422 specialist. This plan has three components. First, species-specific behaviors are 423 encouraged. All animals have access to toys and other manipulata, some of which will 424 be filled with food treats (e.g. frozen fruit, peanut butter, etc.). These are rotated on a 425 regular basis. Puzzle feeders foraging boards, and cardboard tubes containing small 426 food items also are placed in the cage to stimulate foraging behaviors. Adjustable 
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All mouse strains used in this study were of C57BL/6 background unless otherwise indicated.
463
The wild type strain of M. tuberculosis (Mtb) Erdman was used in these studies. Bacteria were 464 cultured in 7H9 medium containing 0.05% Tween 80 and OADC enrichment (Becton Dickinson).
465
For infections, mycobacteria were suspended in phosphate-buffered saline (PBS)-Tween 80 466 (0.05%); clumps were dissociated by sonication, and ~100 CFU were delivered via the respiratory 
525
Serial scans were performed throughout the study to track disease progression and changes 526 during drug treatment. Total FDG activity of the lungs was measured over the course of 527 infection and drug treatment as previously described (19) . Granulomas identified on scans were 528 denoted, measured (mm) and standard uptake values (SUVR) were determined to assess 529 metabolic activity, a readout for inflammation. SUVR values were normalized to muscle and 530 SUVR and size measurements were determined at each scan over time to compare pre-and 531 post-drug treatment. Each animal was scanned prior to necropsy to identify granulomas for 532 matching at necropsy; granulomas > 1mm are distinguishable by PET/CT.
534
Macaque Necropsy
535
Necropsies were performed as previously described. In short, multiple tissues (granulomas, lung 536 lobes, thoracic lymph nodes, peripheral lymph nodes, liver, spleen, bone marrow) were excised 537 and homogenized into single-cell suspensions for assessment of bacterial burden and 538 immunological assays. Granulomas were individually excised (PET/CT identified and others not 539 identified on scans) and split (size permitting) with one-half for homogenization and single cell 540 suspension and the other half processed for histological analysis. Bone marrow samples were 541 obtained from the sternum, with a portion sent for histological analysis while single cell 542 suspensions were acquired as previously described (35). Bacterial burden was assessed from 543 each tissue by plating serial dilutions on 7H11 agar plates and incubated at 37°C in 5% CO2 for 544 21 days before enumeration of Mtb CFU.
546
Flow cytometry and Immunoassays
Mice. Single cell suspensions were prepared from the infected mouse organs. Briefly, lung tissue 548 was digested with Collagenase type IV/DNaseI and passed through 40 µm cell strainers to obtain 549 single cell suspension. Red blood cells were lysed using Tris-buffered Ammonium Chloride (ACT)
